Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment
The European Medicines Agency grants Orphan Designation to Candel Therapeutics' CAN-2409, highlighting its potential to address the significant unmet medical need in pancreatic cancer treatment across Europe.
Candel Therapeutics, Inc. has announced that the European Medicines Agency (EMA) has granted Orphan Designation to its pancreatic cancer drug, CAN-2409, marking a significant milestone in the treatment of this challenging disease. This designation complements similar recognitions from the U.S. Food and Drug Administration (FDA), including Orphan Drug Designation and Fast Track Designation, underscoring the global potential of CAN-2409 in addressing pancreatic ductal adenocarcinoma (PDAC).
CAN-2409 is an innovative immunotherapy designed to induce an individualized immune response against solid tumors. Its mechanism involves converting a prodrug into DNA-incorporating nucleotide analogs, leading to immunogenic cell death and the release of tumor antigens. This approach has shown promise in transforming the tumor microenvironment from 'cold' to 'hot,' enhancing immune infiltration and extending patient survival, as evidenced by phase 2a clinical trial results.
The EMA's Orphan Designation offers Candel Therapeutics several benefits, including reduced regulatory fees and up to 10 years of market exclusivity in the European Union, if approved. This recognition, alongside the drug's existing FDA designations, highlights the therapeutic potential of CAN-2409 in treating PDAC and other solid tumors, offering hope to patients with limited treatment options.
With over 1,000 patients dosed to date and a favorable tolerability profile, CAN-2409 represents a promising advancement in cancer immunotherapy. The company's commitment to advancing CAN-2409 through global regulatory pathways underscores its dedication to addressing the unmet needs of cancer patients worldwide.